Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 04:16pm CEST

A generic version of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone which has been developed by Mylan N.V.(NASDAQ:MYL) has been approved by the U.S. Food and Drug Administration. Copaxone is a blockbuster drug that is used in the treatment of multiple sclerosis.

The approval of the copaxone generic was a surprise to both Teva and Mylan since they had not been expecting it to happen so soon. This came a day after the FDA announced that measures would be introduced with a view to speeding up the approval of generics of complex drugs such as copaxone so that they can get to the market faster and assist in addressing the increasing cost of drugs.

Blockbuster drug

Copaxone is not only the leading therapy for multiple sclerosis in the world but is also the best-selling drug ever developed by Teva. Last year it generated revenues amounting to over $4 billion for the pharmaceutical giant headquartered in Tel Aviv, Israel.

According to Teva, the launch of the generic version of Copaxone was being done prior to the resolution of a couple of patent appeals. This implies that Mylan would end up paying significant damages in the event that Teva prevailed.

Two varying doses of the generic were approved by the FDA and this include the 40 mg dose and the 20mg dose. In this year’s second quarter, over 85% of the Copaxone prescriptions were made for the 40 mg dose.

Loss for Teva

According to analysts the approval amounted to a win for Mylan and a loss for Teva and projected that this would be reflected in both this year’s and next year’s earnings. Mylan’s first generic-version application for Copaxone was filed in 2009.

“Bottom line, this is incrementally positive for Mylan while for Teva both a negative surprise and a cash flow hit to 2018,” wrote Randall Stanicky, an RBC analyst, in a client note.

Two months ago U.S. Congress launched an investigation on drug pricing and Teva was among the pharmaceutical companies contacted over the cost of its multiple sclerosis drug. In 2017 the annual cost for the 20 mg dose of Copaxone is over $90,000 despite the fact that it was unveiled in 1996 and back then it used to cost approximately $8,000.

On Wednesday shares of Mylan N.V. rose by 16.20% to close the day at $37.80.

The post Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
09/22TEVA PHARMACEUTICAL INDUSTRIES : Perry county man pleads guilty to crimes relate..
AQ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
09/20TEVA PHARMACEUTICAL INDUSTRIES : An Application for the Trademark "ACTAVIS" Has ..
AQ
09/20TEVA PHARMACEUTICAL INDUSTRIES : Announces Early Results of Debt Tender Offer an..
AQ
09/19TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. Approval of AJOVYTM Injection, t..
AQ
09/18TODAY’S RESEARCH REPORTS ON STOCKS T : Teva Pharmaceutical and TG Therapeutics
AC
09/18TEVA PHARMACEUTICAL INDUSTRIES : Announces Early Results of Debt Tender Offer an..
BU
09/17Amazon and Apple slide; Caterpillar and ConocoPhillips rise
AQ
09/17FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine
AQ
09/15TEVA PHARMACEUTICAL INDUSTRIES : FDA Approves Teva's Migraine Drug Ajovy -- Upda..
DJ
More news
News from SeekingAlpha
07/11YOUR DAILY PHARMA SCOOP : IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/10Pricing transparency law in California having effect, drug makers nix planned.. 
07/10Crinetics Pharmaceuticals Readies $80 Million IPO 
07/09Biotechs give up gains after Trump tweet on prices 
Financials ($)
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 22,0 $
Spread / Average Target -11%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED36.04%25 142
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092